Integrating HDAd5/35++ vectors as a new platform for HSC gene therapy of hemoglobinopathies by Li, C. et al.
Original ArticleIntegrating HDAd5/35++ Vectors
as a New Platform for HSC Gene
Therapy of Hemoglobinopathies
Chang Li,1,6 Nikoletta Psatha,2,6 Hongjie Wang,1 Manvendra Singh,4 Himanshu Bhusan Samal,4 Wenli Zhang,5
Anja Ehrhardt,5 Zsuzsanna Izsvák,4 Thalia Papayannopoulou,2 and André Lieber1,3
1Division of Medical Genetics, Department of Medicine, University of Washington, Box 357720, Seattle, WA 98195, USA; 2Division of Hematology Department of
Medicine, University of Washington, Seattle, WA 98195, USA; 3Department of Pathology, University of Washington, Seattle, WA 98195, USA; 4Max-Delbrück-Center
for Molecular Medicine, Berlin, 13092 Germany; 5Witten/Herdecke University, Witten, 58448, GermanyWe generated an integrating, CD46-targeted, helper-depen-
dent adenovirus HDAd5/35++ vector system for hematopoietic
stem cell (HSC) gene therapy. The 12-kb transgene cassette
included a b-globin locus control region (LCR)/promoter
driven human g-globin gene and an elongation factor alpha-1
(EF1a)-mgmtP140K expression cassette, which allows for drug-
controlled increase of g-globin-expressing erythrocytes. We
transduced bone marrow lineage-depleted cells from human
CD46-transgenic mice and transplanted them into lethally
irradiated recipients. The percentage of g-globin-positive cells
in peripheral blood erythrocytes in primary and secondary
transplant recipients was stable and greater than 90%. The
g-globin level was 10%–20% of adult mouse globin. Transgene
integration, mediated by a hyperactive Sleeping Beauty SB100x
transposase, was random, without a preference for genes. A sec-
ond set of studies was performed with peripheral blood CD34+
cells from mobilized donors. 10 weeks after transplantation of
transduced cells, human cells were harvested from the bone
marrow and differentiated ex vivo into erythroid cells.
Erythroid cells expressed g-globin at a level of 20% of adult
a-globin. Our studies suggest that HDAd35++ vectors allow
for efficient transduction of long-term repopulating HSCs
and high-level, almost pancellular g-globin expression in eryth-
rocytes. Furthermore, our HDAd5/35++ vectors have a larger
insert capacity and a safer integration pattern than currently
used lentivirus vectors.Received 28 November 2017; accepted 8 February 2018;
https://doi.org/10.1016/j.omtm.2018.02.004.
6These authors contributed equally to this work.
Correspondence: André Lieber, University of Washington, Box 357720, Seattle,
WA 98195, USA.
E-mail: lieber00@uw.eduINTRODUCTION
HSC Gene Therapy
Hemoglobinopathies (b-thalassemia and sickle cell disease) are the
most frequent monogenic diseases worldwide, with approximately
5% of the world population carrying a hemoglobin disorder trait.1
Current hematopoietic stem cell (HSC) gene therapy for hemoglobin-
opathies involve self-inactivating lentivirus (SIN-LV)-based vectors
expressing b-globin (either wild-type or anti-sickling variants of
b-globin) or the fetal form g-globin. Therapeutic genes are under
the control of b-globin locus control region (LCR) versions for
erythroid-specific, position-independent expression. For HSC trans-142 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20
This is an open access article under the CC BY license (http://creatiduction, SIN-LV-globin vectors are incubated ex vivo with CD34+
cells for 2 to 3 days under conditions that support cell cycling.
Ex vivo transduced HSCs are then transplanted into myelo-
conditioned recipients. Trials for b-thalassemia and sickle cell disease
showed a good safety profile and resulted in a significant reduction of
transfusion requirements for beta0/beta0 thalassemia patients and
improved quality of life.2–6 These studies also revealed a number of
problems. Because the vectors require an erythroid-specific LCR,
SIN-LV vectors for globin gene therapy are relatively large and there-
fore difficult to produce at high titers. This in turn influences the cost
for gene therapy. Because of the structure and/or size of globin
SIN-LV vectors, the HSC transduction frequency is relatively low.5
Although no leukemic events have been found in patients treated
with SIN-LV vectors, their preference for integrating into active genes
and transformation events seen in vitro after HSC transduction7
create a challenge for HSC gene therapy.HDAd5/35++ Vectors
According to a 2017 count of clinical gene therapy trials, adenovirus
vectors are the most often used vectors in clinical gene therapy trials
(21.2%) (http://abedia.com/wiley/vectors.php). In the context of our
work on Ad biology, we identified CD46 as the high-affinity receptor
for a number of Ads, including serotype 11, 16, 21, 35, and 50.8 CD46
is expressed on all humanHSCs.9 Recently, we have shown that CD46
is expressed at higher levels on mouse and human HSCs than on
more differentiated bone marrow and blood cells.10 The receptor-
interacting moiety in the capsid of adenoviruses is the C-terminal
globular trimeric fiber domain, called the fiber knob. We and others
have shown that adenovirus vectors containing the Ad35 fiber or fiber
knob (Ad5/35) efficiently transduce HSCs in vitro.11–13 Ad5/35 vector
transduction of HSCs did not require cell division.11 The incoming18 ª 2018 The Author(s).
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgAd vector genome is bound to viral proteins that mediate nuclear
import.14 To avoid HSC cytotoxicity associated with first-generation
Ad5/35 vectors,15 we generated helper-dependent HDAd5/35++
vectors devoid of all viral genes. These vectors contained a series of
mutations in the Ad35 fiber knob that increased the affinity to
CD46 more than 25-fold and allowed for more efficient cell transduc-
tion at lower MOIs.16 The production of HDAd5/35++ vectors
involves the co-transfection of a plasmid containing the HDAd vector
genome and a helper virus that provides all structural and non-
structural viral proteins but cannot be packaged. Virus rescue is
done at a small scale (6-cm plates). The virus is produced at a large
scale in a 2-l spinner culture that routinely yields >1  1013 viral
particles (vp) per spinner.17 The purified virus preparation can then
be used as a stock for further large-scale production. Based on our
experience, HDAd5/35++ production can easily be established
following the protocol by D. Palmer and P. Ng.17
HDAd5/35++ vectors do not integrate into the cellular genome. This,
however, is a requirement for HSC gene therapy because an episomal
vector would be lost after several cell divisions. We therefore incorpo-
rated a Sleeping Beauty transposase-based system that mediates trans-
gene integration. This system consists of an HDAd5/35++ transposon
vector that carries the transgene expression cassette, which is flanked
by inverted transposon repeats (IRs) and flippase recognition target
(FRT) sites. The second HDAd5/35++ vector provides both Flpe
recombinase and an activity-enhanced Sleeping Beauty transposase
(SB100x)18 in trans. Upon co-infection of both vectors, Flpe mediates
the circularization of the transposon through the FRT sites. SB100x
then randomly integrates the transposon into the host genome
through interaction with the IRs.
In a recent study, we tested SB100x-armed HDAd5/35++ vectors for
in vivoHSC transduction.10,19 The approach involved the subcutane-
ous injection of granulocyte-colony stimulating factor (GCSF)/
AMD3100 to mobilize HSCs from the bone marrow into the periph-
eral blood stream and the intravenous injection of the integrating
HDAd5/35++ vector system. We demonstrated in adequate mouse
models that our vectors allow for the stable transduction of HSCs,
with a preference for transducing primitive HSCs (Lin–/Sca-1+/
c-Kit+ [LSK] cells, colony-forming unit [CFU], long-term repopulat-
ing cells).10 30 weeks after in vivo transduction, GFPmarking in bone
marrow HSCs was in the range of 5%–10%. The percentage of
GFP-expressing primitive HSCs capable of forming multi-lineage
progenitor colonies (CFUs) increased from 4% of all CFUs at week
4 to 16% at week 12, indicating transduction and expansion of
long-term surviving HSCs. We found that the majority of GFP+
HSCs in the bone marrow are quiescent, not efficiently contributing
to downstream differentiation.We used an in vivoHSC chemo-selec-
tion approach to give gene-modified HSCs a proliferation stimulus.20
This system is based on a mutant of the O6-methylguanine-DNA
methyltransferase (mgmtP140K) gene that confers resistance to
methylating agents (e.g., O6-benzylguanine [O6-BG] plus bis-
chloroethylnitrosourea [BCNU] or temozolomide).21–23 We showed
in mobilized, in vivo transduced mice that 4 cycles of O6-BG/BCNUMolecutreatment resulted in stable GFP expression in 80% of peripheral
blood cells.20
Here, we generated an integrated HDAd5/35++ vector with a 11.8-kb
transgene cassette containing a 5-kb b-globin LCR/promoter version
controlling the expression of a full-length g-globin gene as well as an
elongation factor alpha-1 (EF1a)-promoter driven mgmtP140K
expression cassette. We studied g-globin expression after mouse
and humanHSC ex vivo transduction and subsequent transplantation
into myeloablated recipients. These studies are an important step
toward our final goal, which is in vivo HSC gene therapy of
hemoglobinopathies.
RESULTS
HDAd-g-Globin/mgtm Vector
For b-thalassemia gene therapy to be curative, it is essential that the
transferred g-globin gene be expressed in erythroid cells at high
levels, without position effect of integration and transcriptional
silencing. To achieve this, the b-globin LCR is required.24 Here, we
used a 5.0-kb b-globin LCR version that contained the key DNase I
hypersensitivity (HS) HS1–HS4 regions and the b-globin promoter
(Figure 1A, upper panel). The LCR is driving a full-length human
g-globin (HBG1) gene, including the 30 UTR, which stabilizes
g-globin RNA in (enucleated) erythrocytes. There are two known
variants of the HBG1 gene in the human population with a single
amino acid variation (76-Isoleucine or 76-Threonine). We used in
our studies the 76-Ile HBG1 variant, which has a range in frequency
of 13% in Europeans to 73% in East Asians. The vector also contained
an mgmtP140K expression cassette mechanism for in vivo selection.
The mutant mgmt gene is under the control of the ubiquitously active
EF1a promoter, therefore allowing for selection at the level of HSCs,
progenitors, and differentiated cells. The in vivo selection system will
make it possible to maximize the frequency of g-globin-expressing
erythrocytes. A 1.2-kb chicken HS4 chromatin insulator25 was in-
serted between the g-globin and mgmtP140K expression cassettes to
avoid promoter interference. In the HDAd5/35++ g-globin/mgmt
vector, the transposon to be integrated into the host genome will
have a length of 11.8 kb. The HDAd-SB vector that provides
the hyperactive SB100x transposase in trans (Figure 1A, lower
panel) has been described recently.10 In this study, the HDAd-
g-globin/mgmt and HDAd-SB vectors were produced at a titer of
1  1013vp/mL, without detectable genomic rearrangements.
Studies in hCD46 Transgenic Mice
HDAd5/35++ vectors infect cells through CD46. Although CD46 is
expressed on all nucleated cells in humans, the corresponding ortho-
log in mice is expressed only in the testes. As a model for our in vivo
HSC transduction studies, we used a C57BL/6-based transgenic
mouse model (hCD46tg) that contained the complete human
CD46 locus. These mice express hCD46 in a pattern and at a level
similar to those of humans.26 We used hCD46tg mice as a source
for HSCs in this study (Figure 1B). For ex vivo transduction, bone
marrow cells depleted for differentiated progenitor cells that were
positive for lineage markers (CD5, CD45R, CD11b, Gr-1, 7-4, andlar Therapy: Methods & Clinical Development Vol. 9 June 2018 143
Figure 1. Integrating HDAd5/35++ Vector
(A) Vector structure. In HDAd-g-globin/mgtm, the 11.8-kb transposon is flanked by inverted transposon repeats (IRs) and FRT sites for integration through a hyperactive
SleepingBeauty transposase (SB100x) provided fromanHDAd-SB vector.10 Theg-globin expression cassette contains a 4.3-kb version of the b-globin LCR consisting of four
DNase hypersensitivity (HS) regions and the b-globin promoter.51 The full-length g-globin cDNA, including that 30 UTR (for mRNA stabilization in erythrocytes) was used. The
mgmtP140K gene is under the control of the ubiquitously active EF1a promoter. The bidirectional SV40 poly-adenylation signal is used to terminate transcription.
To avoid interference between the LCR/b-promoter and EF1a promoter, a 1.2-kb chicken HS4 chromatin insulator25 was inserted between the cassettes. The second vector
(HDAd-SB) providesboth Flpe recombinase and theSB100x transposase in trans. Both vectors are helper-dependent adenovirus (HDAd) vectors containing theCD46affinity-
enhanced Ad35++ fiber knob and Ad35 fiber shaft.16 Upon co-infection of both vectors, Flpe mediates the circularization of the transposon through FRT sites. SB100x then
randomly integrates the transposon into the host genome through interaction with the IRs. (B) Schematic of the experiment. Bonemarrow was harvested from hCD46tg mice
and lineage-negative cells (Lin–) were isolated bymagnetic-activated cell sorting (MACS). Lin cells were transducedwith HDAd vectors at a total MOI of 1,000 vp/cell at a ratio
of 1:1. After 1 day in culture, 1  106 transduced cells/mouse were transplanted into lethally irradiated C57BL/6 mice. At week 4, O6-BG/BCNU treatment was started and
repeated every 2weeks for a total of 3 times.With each cycle, 30mg/kgO6-BGwas applied, whereas theBCNUdosewas increased from5mg/kg to 7.5mg/kgand10mg/kg.
Animals were sacrificed at week 12, and bone marrow Lin cells were transplanted into secondary recipients, which were then followed for 16 weeks.
Molecular Therapy: Methods & Clinical DevelopmentTer119) were used. Lineage-negative (Lin) cells are enriched for
HSCs. Immediately after isolation, Lin cells were transduced with
HDAd-g-globin/mgmt + HDAd-SB and incubated overnight in
medium that did not support cell proliferation (“low cytokine”
medium). The ex vivo incubation was kept as short as possible to pre-
serve the multipotency of HSCs. We used anMOI of 1,000 vp/cell, an
MOI that resulted in efficient Lin cell transduction in previous
studies with HDAd5/35++ vectors expressing GFP.10,20 A total of
5  105 transduced Lin cells were transplanted into lethally irradi-
ated C57BL/6 mice. C57BL/6 mice do not express human CD46,
which allows us to follow engraftment of transplanted cells based
on hCD46 by flow cytometry. 4 weeks after transplantation, mice
received three cycles of O6-BG/BCNU treatment and were sacrificed
at week 12 (“primary recipients”). Tissues were analyzed for g-globin
expression. To demonstrate the stable genetic modification of long-
term repopulating HSCs, Lin cells from primary recipients were
again transplanted and secondary recipients were followed for
16 weeks (Figure 1B).
Analysis of blood cells collected at weeks 4, 6, 8, 10, and 12 from pri-
mary recipients showed over 99% engraftment of transplanted cells
(Figure 2A). This was confirmed in spleen and bone marrow samples144 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20analyzed at week 12 after transplantation (Figure 2B). Expression of
g-globin was analyzed by flow cytometry through intracellular stain-
ing with an antibody specific for human g-globin. At 4 weeks, on
average, 80% of blood cells expressed g-globin (Figure 2C).
Notably, 99.8% of blood cells are erythrocytes. Therefore, the fre-
quency of g-globin-positive total blood cells is representative for
erythrocytes. The latter was confirmed by flow cytometry for g-globin
and the erythroid cell marker Ter-119. After initiation of in vivo se-
lection, the percentage of g-globin-expressing blood erythrocytes
reached nearly 100% and was stable over the observation period of
12 weeks. g-globin mRNA levels were three to four orders of magni-
tude higher in HDAd-g-globin/mgmt erythrocytes compared to un-
treated b-YAC mice27 (Figure 2D). g-globin expression was also
analyzed in bone marrow cells that were positive or negative for the
erythroid surface marker Ter-119 (Figures 2E and 2F). The percent-
age of g-globin-expressing cells was 8-fold lower on Ter-119 cells
compared to Ter-119+ cells (Figure 2E). Lower expression levels in
non-erythroid cells were also reflected in the mean fluorescence
intensity (MFI) for g-globin (Figure 2F). g-globin expression levels
in bone marrow cells were 15% of those of adult mouse (a- or
b-like) globin at the level of mRNA (measure by qRT-PCR) (Fig-
ure 2G) and protein (measured by HPLC) (Figure 2H).18
Figure 2. Analysis of Primary Transplanted Mice
(A) Engraftment of transplanted cells based on human CD46 expression on PBMCsmeasured by flow cytometry. Each symbol is an individual animal. (B) Engraftment rates in
blood, spleen, and bone marrow mononuclear cells analyzed at week 12 after transplantation. (C) Percentage of human g-globin-positive cells in peripheral blood cells
measured by flow cytometry. (D) Fold increase in g-globin mRNA in total peripheral blood cells in four treated mice (#1–#4) compared to b-YAC mice. (E–H) Analysis of week
12 bone marrow samples. (E) g-globin expression in erythroid (Ter-119+) and non-erythroid (Ter-119) cells. The right panel shows a representative sample. (F) Mean
fluorescence intensity (MFI) of g-globin in Ter-119+ and Ter-119 cells. (G) Percentage of human g-globin mRNA relative to mouse adult b-like globin RNA. Controls are bone
marrow samples from untreated C57BL/6 mice. (H) HPLC data. Percentage of human g-globin protein relative to mouse adult a- and b-globin protein.
www.moleculartherapy.orgTo evaluate the potential myelotoxicity of the in vivo selection process,
we studied the cellular composition in bone marrow at week 12 (Fig-
ure 3A). Analysis of the frequency of lineage cells showed no signifi-
cant differences between untreated mice and mice that received trans-
duced Lin cells and subsequent in vivo selection. The level of Lin/
Sca1+/cKit+ (LSK)HSCs was also comparable in both groups (0.5%).
To assess potential side effects of SB100x expression, we measured
SB100x mRNA by qRT-PCR (Figure 3B). Although SB100x mRNA
was clearly detectable in Lin cells in culture at day 3 after transduc-
tion, no detectable signals were found in bone marrow mononuclear
cells at weeks 4 and 12 after transplantation. This indicates that the
episomal HDAd-SB vector and, consequently, SB100x expression is
rapidly lost during cell division in transplanted animals.MolecuTo analyze genotoxic effects due to SB100x-mediated transgene integra-
tionandsubsequent invivo selection,weperformedagenome-wide inte-
gration analysis using linear amplification-mediated PCR (LAM-PCR),
followed by Illumina sequencing of genomic DNA isolated at week 12
from bone marrow cells of primary recipients (Figures 3C–3E).
SB100x-mediated transgene integration siteswere randomly distributed
over the mouse genome (Figure 3E). Integrations within exons consti-
tuted2.1%ofall integrationevents. 41.6%of integrationsiteswerewithin
introns, 54.2% in intergenic regions, and 2.1% in untranslated regions
(Figure 3D). The pattern of integration is statistically similar in both
continuous and randommouse genomic windows (Figure 3E).
In conclusion, SB100x-mediated random transgene integration
showed no preference for genes. The in vivo selection process didlar Therapy: Methods & Clinical Development Vol. 9 June 2018 145
Figure 3. Safety Studies
(A) Cellular bone marrow composition in naive mice (control) and treated mice sacrificed at week 12. Shown is the percentage of lineagemarker positive cells (Ter-119+, CD3+,
CD19+, and Gr-1+ cells) and HSCs (LSK cells). (B) SB100x mRNA levels in total bone marrow mononuclear cells measured by qRT-PCR in comparison to mRNA levels of the
house-keeping genemRPL10.DCt = CtSB100xCtmRPL10. Samples were collected at day 3 after in vitro transduction of Lin cells and at weeks 4 and 12 after transplantation of
HDAd-SB+HDAd-g-globin/mgmt transduced Lin cells. No SB100x mRNA signals were detected at weeks 4 and 12. N = 3. (C) Chromosomal distribution of integration sites.
Genomic DNA was isolated from total bone marrow mononuclear cells (week 12 samples pooled from 4 male mice). Shown is the distribution of integrations over the mouse
genome displayed as a fraction of total integrations per chromosome. (D) Percentage of integrations in exons, untranslated regions (UTRs), and intronic and intergenic regions.
(E) Pattern of integration in continuous (blue) and random mouse genomic windows (red). The similarity is statistically significant. Pearson’s Chi-square test: p = 0.1669.
Molecular Therapy: Methods & Clinical Developmentnot change the random integration pattern compared to previous
studies without in vivo selection.10
To further confirm that our approach resulted in genetic modification
of primitive HSCs, we performed a transplantation/repopulation
study in secondary recipients. Lineage-negative bone marrow cells
from primary recipients collected at week 12 after transplantation
were used for secondary transplantation into lethally irradiated
C57BL/6 mice. Analysis of hCD46 expression on PBMCs at weeks
4–16 after secondary transplantation showed engraftment rates of
>90% in all recipients (Figure 4A). The percentage of human
g-globin-positive peripheral red blood cells was also nearly 100%,
indicating that genetically modified HSCs had repopulated the blood
system (Figure 4B). The frequency of g-globin-positive Ter-119+ cells
in blood and bone marrow was in the range of 90%–95% (Figure 4C).
The g-globin expression level in blood cells, measured by HPLC, was
in the range of 7%–12% of mouse adult globin (Figure 4D).
In summary, these data suggest that our vector system targets long-
term repopulating cells and that these cells are maintained through
the selection process.146 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20Studies with Human CD34+ Cells from G-CSF Mobilized Donors
To increase the relevance of our studies with integrating HDAd5/35++
vectors for HSC gene therapy, we performed studies with human
CD34+ cells, a cell fraction that is enriched for HSCs (Figure 5A).
16 hr after recovery of CD34+ cells from cryopreserved stocks in
low-cytokine medium, cells were transduced with HDAd-g-globin/
mgmt+HDAd-SB at a total MOI of 2,000 vp/cell. This MOI conferred
efficient CD34+ cell transduction in previous studies with HDAd5/
35++ vectors.10,28 To assess the effect of HDAd5/35++ transduction
on activation of endogenous g-globin expression in CD34+ cells, we
also transduced cells with an HDAd5/35++ vector containing the
human FVIII gene (HDAd-control). After overnight incubation with
the vectors, CD34+ cells were transplanted into sublethally irradiated
immunodeficient NSG mice. Engraftment rates measured at week 4
after transplantation, based on the hCD45 expression on PBMCs,
were, on average, 10% for both groups. This is in the range that we
observed with this CD34+ cell donor after transplantation of untrans-
duced cells15,28,29 and suggests that HDAd5/35++ transduction does
not reduce the engraftment potential of CD34+ cells. At week 4, 6,
and 8 after transplantation, mice transplanted with HDAd-g-globin/
mgtm+HDAd-SB transducedHSCs receivedO6-BG/BCNU treatment.18
Figure 4. Analysis of Secondary Recipients
(A) Engraftment based on hCD46 expression on
PBMCs. (B) Percentage of human g-globin-positive cells
in peripheral blood cells. (C) Percentage of human
g-globin-positive cells in blood and bonemarrow Ter119+
cells. (D) Percentage of human g-globin protein relative to
mouse adult a- and b-globin protein in total peripheral
blood cells at week 16.
www.moleculartherapy.orgAll animals were sacrificed at week 10. NSG mice do not support the
differentiation of human HSCs into erythrocytes, which is required
to achieve expression of the ectopic g-globin gene from the b-globin
LCR.We therefore isolated human CD45+ cells from the bone marrow
of transplanted mice and incubated them in a medium that triggers
their erythroid differentiation. In agreement with published data,30 a
relatively high frequency of cells expressing endogenous g-globin
(40%) was observed after erythroid differentiation in HDAd-control
transduced samples. A similar percentage of g-globin-positive cells
was observed at day 18 of erythroid differentiation of naive (untrans-
duced) CD34+ cells recovered from cryopreservation (data not shown).
This indicates that these culture conditions activate fetal globin synthe-
sis in CD34+ cells. Importantly, the frequency of g-globin-positive cells
was significantly higher (75%–80%) in erythroid cells obtained from
mice that were transplanted with HDAd-g-globin/mgmt transduced
HSCs (p < 0.01) (Figure 5B). g-globin RNA levels were4-fold higher
in HDAd-g-globin/mgmt samples than in HDAd-control samples,
whereas mRNA levels for b-globin were comparable (Figure 5C). We
also analyze levels of g- and adult a- and b-globin chains by HPLC.
The g-to-a ratio in HDAd-g-globin/mgtm samples suggests ectopic
g-globin expression at a level of 20% of a chains (Figure 5D). Interest-
ingly, ectopic g-globin expression decreased the levels of b-globin, as
indicated by the ratio of b-to-a, most likely to keep the mean corpus-
cular hemoglobin concentration in the physiological range. Analysis of
lineage-positive cells in the bone marrow at week 10 showed compara-
ble frequencies in CD34+ cells but higher levels of CD33+, CD3+, and
hGlyA+ (erythroid) cell fractions in the HDAd-g-globin/mgmt group
(Figure 5E), which was most likely the result of in vivo selection.
Overall, our data demonstrate efficient g-globin expression after
ex vivo HSC transduction with integrating HDAd5/35++ vectors
and subsequent transplantation and erythroid differentiation.Molecular Therapy: MethodsDISCUSSION
Currently, SIN lentivirus and rAAV6 vectors
are used for HSC transduction.31–33 Inte-
grating HDAd5/35++ vectors have a number
of potential advantages over SIN-LV and
rAAV vectors for globin gene therapy.
(1) The production of HD-Ad5/35++ vectors
does not require large-scale plasmid transfec-
tion and yields high viral titers, which will
greatly reduce the costs of clinical gene ther-
apy. Based on our experience, starting from
an HDAd5/35++ virus stock and using themanufacturing protocol developed by Philip Ng,17 the costs for
laboratory-grade HDAd5/35++ vector is about $600-$1,000 per
1  1013 viral genomes. For comparison, the production of the
same amount of a rAAV vector would cost 10-fold more.
Strimvelis, a lentivirus-based HSC gene therapy is sold for
$600,000–$700,000 per patient. This price includes the complete
current Good Manufacturing Practices (cGMP) procedure of HSC
harvesting, transduction, and transplantation. (2) In contrast to
lentivirus vectors, HDAd5/35++ vectors do not require cell cycling
for transduction.11 (3) Although the maximum insert capacity of
SIN-LV and rAAV vectors is 8 and 5 kb, respectively, HDAD5/
35++ vectors have an insert capacity of 30 kb. This is relevant for
reaching curative levels of therapeutic globin, which is thought to
require the full-length (26 kb) b-globin LCR.24 (4) Integration is
mediated by the SB100x transposase system, which functions
independently of cellular factors. (5) HDAd5/35++ vectors armed
with the SB100x-based integration system do not have a preference
of transgene integration into active genes.10 In contrast, both lenti-
virus and rAAV vectors have a preference for integrating into active
genes.33,34
Here, we demonstrated the utility of integrating HDAd5/35++ vector
for gene therapy of hemoglobinopathies. We generated an integrated
HDAd5/35++ vector with an 11.8-kb transgene cassette containing a
5-kb b-globin LCR/promoter version controlling the expression of a
full-length g-globin gene as well as an EF1a-mgmtP140K expression
cassette. The 11.8-kb transgene cassette would not fit into SIN-LV
vectors, which have an insert capacity of 8.5 kb. We incorporated
the mgmtP140K-based in vivo selection system into our vector because
this would allow for drug-controlled increase of the g-globin level if
levels start declining and patients become transfusion-dependent
again, a problem seen with globin-expressing SIN-LV vectors.& Clinical Development Vol. 9 June 2018 147
Figure 5. Studies with Human CD34+ Cells
(A) Schematic of the experiment. Human CD34+ cells
were transduced ex vivo, and 24 hr later, transplanted into
sublethally irradiated NOG mice. Mice that received the
HDAd-g-globin/mgmt vector were treated with O6-BG/
BCNU as indicated. 10 weeks after transplantation, mice
were sacrificed, and bone-marrow-derived humanCD34+
cells were subjected to erythroid in vitro differentiation.
(B) Percentage of human cells expressing g-globin at day
14 and 18 of erythroid differentiation. (C) Adult (b-globin)
and g-globin mRNA in cells at day 14 of in vitro differen-
tiation. (D) HPLC for globin chains. g/a-globin and beta/
a-globin percentages at day 18 of erythroid differentiation.
(E) Percentage of human-lineage-marker-positive cells in
the bone marrow at week 9 after transplantation.
Molecular Therapy: Methods & Clinical DevelopmentFocusing on introducing the g-globin gene rather than the b-globin
gene has the advantage that it can be used for gene therapy of both
b-thalassemia and sickle cell disease.
In a first set of studies, we transduced bone marrow Lin cells from
hCD46tg ex vivo and transplanted them into lethally irradiated recip-
ients. Engraftment rates were 100% and stable, indicating that vec-
tor transduction did not negatively affect the viability and function of
HSCs. The expression of g-globin in primary and secondary recipi-
ents in peripheral blood erythrocytes and erythroid cells in the
bone marrow was almost pancellular (90%–100%). The g-globin level
was 10%–20% of adult mouse globin. In previous studies with g-
globin lentivirus vectors, these levels resulted in an amelioration of
murine b-thalassemia and sickle cell diseases under conditions in
which g-globin-expressing erythroid cells have a survival advan-
tage.35–37 Stable g-globin expression in primary and secondary recip-
ients and the demonstration of random transgene integration by
genome-wide sequencing suggest (1) that the HDAd535++ vector
system targeted long-term repopulating HSCs with high efficiency.
This is potentially due to the facts that the vector uses CD46 for infec-
tion, a receptor that is expressed at higher levels on primitive HSCs
than on more differentiated bone marrow cells and that it can trans-
duce non-dividing HSCs. (2) The SB100x can integrate an 11.8-kb148 Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018transposon. So far, SB100x-mediated integra-
tion had only been shown for transposons
smaller than 6 kb. (3) The integrated g-globin
transgene cassette escapes gene silencing.
(4) The integration site analysis indicates that
the in vivo selection process did not change
the random integration pattern, i.e., did not
result in clonal dominance.
Our studies showed g-globin background
expression in non-erythroid cells. This can
potentially be addressed by replacing the 5-kb
LCR with the 26-kb version. Potentially, the
26-kb LCR version can mediate higher g-globin
levels, which is of importance for the treatmentof sickle cell disease. Notably, we have generated HDAd5/35 vectors
containing the 26-kb LCR before.38 However, these vectors were not
armed with the SB100x-based integration system. Further improve-
ments could also include the modification of the HDAd5/35++
vectors for targeted integration into a single pre-selected site.39
Because mice received lethal irradiation and thus developed tolerance
to foreign transgene products, vector/transgene immunogenicity has
to be considered in settings with only partial myeloablation. In this
context, it has to be noted that HDAd5/35++ vectors do not express
viral proteins and that the SB100x-encoding vector is lost after several
cell divisions. Also, the use of human transgenes (g-globin andmgmt)
should not trigger corresponding immune responses in patients.
A second set of studies was performed with peripheral blood CD34+
cells from mobilized healthy donors. Transduced cells were trans-
planted into sublethally irradiated NSG mice. Because this model
does not support the differentiation of human HSCs into differenti-
ated erythroid cells, engrafted human HSCs were harvested from
the bone marrow at week 10 after transplantation and incubated
ex vivo with cytokines that support erythroid differentiation. At the
end of the differentiation process, we detected ectopic g-globin
expression at a level that was 20% of that of adult a-globin. In a
www.moleculartherapy.orgprevious in vitro study with g-globin-expressing SIN-LV vectors,
these levels were considered to be therapeutic in erythroid progeny
of b-thalassemia CD34+ cells.40
There is no clinical experience with HDAd5/35++ vectors, and studies
in non-human primates are still ongoing (A.L., unpublished data).
First-generation Ad5/35 vector has been used in clinical trials for
ex vivo T cell transduction.41,42 Helper-dependent vectors derived
from serotype 5 (HDAd5) have been tested inmice, dogs, and non-hu-
man primates for the treatment of diseases, including Apoplipoprotein
A (ApoE) deficiency, atherosclerosis, a1 anti-trypsin deficiency, cystic
fibrosis, Duchenne muscular dystrophy, glioblastoma, and infectious
diseases (for a review, see Rosewell et al.43 and Brunetti-Pierri
et al.44). There is a published report on the clinical use of HDAd5
vectors.45 Furthermore, Aevi Genomic Medicine’s website indicates
clinical development of a HDAd vector expressing the metabotronic
glutamate receptor for treatment of ADHD.
In summary, although our focus is still on developing our in vivoHSC
gene therapy approach,10,19,20 the studies presented here suggest that
our vectors are valuable for ex vivoHSC gene therapy of hemoglobin-
opathies. Setting up the clinical grade manufacturing of HDAd5/
35++ vectors is a major focus of our upcoming efforts.
MATERIALS AND METHODS
Generation of Transposon Vector HDAd-g-Globin/mgmt
The shuttle plasmid pBS-mLCR was generated by DNA synthesis
(GenScript, Piscataway, NJ). This plasmid consists of the core region
of four erythroid-specific DNase I hypersensitive sites, HS4 (http://
genome.ucsc.edu/), human chromosome 11: 5,288,038/5,289,100),
HS3 (chromosome 11 [Chr11]: 5,284,251/5,285,551), HS2 (Chr11:
5,280,523/5,281,381), and HS1 (5,275,644/5,276,717), the human
b-globin promoter (Chr11:5,227,022/5,227,684), and the chromatin
insulator cHS4. Human g-globin gene and its 30 UTR region
(Chr11:5,247,139/5,249,804)46 (a generous gift from Dr. Qiliang
Li) was then inserted into pBS-mLCR downstream of the human
b-promoter. The human EF1a promoter-mgmt(p140k)-SV40pA
cassette was inserted downstream of the cHS4 (pBS-mLCR-g-globin-
mgmt). The expression cassette mLCR-g-globin-mgmt was then
released by PacI and inserted into plasmid pHM5-T/Ef1a-GFP-
FRT210 by replacing the EF1a-GFP cassette (pHM5-T/mLCR-g-
globin-mgmt-FRT2). The transposon contained the g-globin and
mgmt. genes. Expression cassettes flanked by FRT sites were then
released by I-CeuI/PI-SceI restriction enzyme digestion and inserted
into a modified pWE15-HCA plasmid (pWEHCA-mLCR-g-globin-
mgmt-FRT2). The pWE-HCA plasmid15 was modified by inserting
I-CeuI/PI-SceI sites into the ClaI site. The resulting plasmids
were packaged into phages using Gigapack III plus packaging Extract
(Agilent Genomics) and propagated. To generate HDAd-g-globin/
mgmt virus, the viral genome were released by FseI digestion from
the plasmid for rescue in 116 cells47 with AdNG163-5/35++, an
Ad5/35++ helper vector containing chimeric fibers composed of the
Ad5 fiber tail, the Ad35 fiber shaft, and the affinity-enhanced
Ad35++ fiber knob.10MolecuThe generation of HDAd-SB has been described previously.10 Helper
virus contamination levels were below 0.05%. All preparations were
free of bacterial endotoxin.
CD34+ Cell Culture
CD34+ cells from G-CSF-mobilized adult donors were recovered
from frozen stocks and incubated overnight in Iscove’s modified Dul-
becco’s medium (IMDM) supplemented with 10% heat-inactivated
fetal calf serum (FCS), 1% BSA, 0.1 mmol/L 2-mercaptoethanol,
4 mmol/L glutamine and penicillin/streptomycin, Flt3 ligand
(Flt3L, 25 ng/mL), interleukin-3 (IL-3) (10 ng/mL), thrombopoietin
(TPO) (2 ng/mL), and stem cell factor (SCF) (25 ng/mL). Cytokines
and growth factors were from Peprotech (Rocky Hill, NJ). CD34+
cells were transduced with virus in low attachment 12-well plates.
Lin– Cell Culture
Lineage-negative cells were isolated from total mouse bone marrow
cells by MACS using the Lineage Cell Depletion kit from Miltenyi
Biotech (Bergisch Gladbach, Germany). Lin cells were cultured in
IMDM supplemented with 10% FCS, 10% BSA, Pen-Strep, glutamine,
10 ng/mL human TPO, 20 ng/mL mouse SCF, and 20 ng/mL human
Flt3L.
Erythroid In Vitro Differentiation
Differentiation of human HSCs into erythroid cells was done based
on the protocol developed by Douay et al.48 In brief, in step 1, cells
at a density of 104 cells/mL were incubated for 7 days in IMDM sup-
plemented with 5% human plasma, 2 IU/mL heparin, 10 mg/mL insu-
lin, 330 mg/mL transferrin, 1 mM hydrocortisone, 100 ng/mL SCF,
5 ng/mL IL-3, 3 U/mL erythropoietin (Epo), glutamine, and Pen-
Strep. In step 2, cells at a density of 1  105 cells/mL were incubated
for 3 days in IMDM supplemented with 5% human plasma, 2 IU/mL
heparin, 10 mg/mL insulin, 330 mg/mL transferrin, 100 ng/mL SCF,
3 U/mL Epo, glutamine, and Pen/Strep. In step 3, cells at a density
of 1  106 cells/mL were incubated for 12 days in IMDM supple-
mented with 5% human plasma, 2 IU/mL heparin, 10 mg/mL insulin,
330 mg/mL transferrin, 3 U/mL Epo, glutamine, and Pen-Strep.
Globin HPLC
Individual globin chain levels were quantified on a Shimadzu Prom-
inence instrument with an SPD-10AV diode array detector and an
LC-10AT binary pump (Shimadzu, Kyoto, Japan). A 40%–60%
gradient mixture of 0.1% trifluoroacetic acid in water/acetonitrile
was applied at a rate of 1 mL/min using a Vydac C4 reversed-phase
column (Hichrom, UK).
Flow Cytometry
Cells were resuspended at 1  106 cells/100 mL in PBS supplemented
with 1% FCS and incubated with FcR blocking reagent (Miltenyi
Biotech, Auburn CA) for 10 min on ice. Next, the staining antibody
solution was added in 100 mL per 106 cells and incubated on ice for
30 min in the dark. After incubation, cells were washed once in
FACS buffer (PBS, 1% FBS). For secondary staining, the staining
step was repeated with a secondary staining solution. After thelar Therapy: Methods & Clinical Development Vol. 9 June 2018 149
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LSRII flow cytometer (BD Biosciences, San Jose, CA). Debris was
excluded using a forward scatter area and sideward scatter-area
gate. Single cells were then gated using a forward scatter height and
forward scatter-width gate. Flow cytometry data were then analyzed
using FlowJo (version 10.0.8). For flow analysis of LSK cells, cells
were stained with biotin-conjugated lineage detection cocktail (Milte-
nyi Biotec, San Diego, CA) and antibodies against c-Kit and Sca-1 as
well as allophycocyanin (APC)-conjugated streptavidin. Other
antibodies from eBioscience (San Diego, CA) included anti-mouse
LY-6A/E (Sca-1)-PE-Cyanine7 (clone D7), anti-mouse CD117
(c-Kit)-PE (clone 2B8), anti-mouse CD3-APC (clone 17A2), anti-
mouse CD19-PE-Cyanine7 (clone eBio1D3), and anti-mouse Ly-66
(Gr-1)-PE (clone RB6-8C5). Other antibodies from Miltenyi Biotec
included anti-human CD45-APC (clone 5B1), anti-human CD3-
PE/Cy7 (clone REA613), anti-human CD34-PE (clone AC136), and
anti-human Glycophorin A-VioBlue (clone REA175). Anti-human
CD19-PE (clone: HIB19) and anti-human CD33-BV421 (WM53)
were from BD Biosciences. Anti-mouse Ter-119-APC (clone:
Ter-119) was from BioLegend (San Diego, CA).
Intracellular Flow Cytometry Detecting Human g-Globin
Expression
The FIX and PERMcell permeabilization kit (Thermo Fisher Scientific)
was used, and the manufacturer’s protocol was followed. Briefly,1
106 cells were resuspended in 100 mL FACS buffer (PBS supplemented
with 1%FCS), 100mL reagentA (fixationmedium)was added and incu-
bated for 2 to 3min at room temperature, and 1mLpre-cooled absolute
methanol was then added, mixed, and incubated on ice in the dark
for 10 min. The samples were then washed with FACS buffer
and resuspended in 100 mL reagent B (permeabilization medium)
and 1 mg hemoglobin g antibody (Santa Cruz Biotechnology, cat#
sc-21756 PE), incubated for 30 min at room temperature. After the
wash, cells were resuspended in FACS buffer and analyzed. For
erythroid and g-globin double staining, cells were stained with APC
anti-mouse Ter-119 antibody first, and then washed and proceeded
with fixation medium as described above.
Real-Time RT-PCR
Total RNA was extracted from 50 to 100 mL blood by using TrIzol
reagent (Thermo Fisher Scientific) following the manufacturer’s
phenol-chloroformextractionmethod.Quantitect reverse transcription
kit (QIAGEN) and power SYBR greenPCRmastermix (ThermoFisher
Scientific) were used. Real-time qPCRwas performed on a Steponeplus
real-time PCR system (AB Applied Biosystems). The following primer
pairs were used: mouse RPL10 (house-keeping) forward, 50-TGAA
GACATGGTTGCTGAGAAG-30, and reverse, 50-GAACGATTTGG
TAGGGTATAGGAG-30; human g-globin forward, 50-GTGGAA
GATGCTGGAGGAGAAA-30, and reverse, 50-TGCCATGTGCCTTG
ACTTTG-30; mouse b-major globin forward, 50- ATGCCAAAGT
GAAGGCCCAT-30, and reverse, 50- CCCAGCACAATCACGAT
CAT-30, and human b-globin forward, 50-CTCATGGCAAGA
AAGTGCTCG-30, and reverse, 50-AATTCTTTGCCAAAGTG
ATGGG-30. For qRT-PCR of SB100x mRNA, the following primers150 Molecular Therapy: Methods & Clinical Development Vol. 9 June 20were used: SB100x forward, 50-AGCCACTGCTCCAAAACCGA
CA-30, and reverse, 50-AAGCCTCCCCCTTCTTCCTCCA-30.Integration Site Analysis
Amplification of genomic DNA junctions was performed by linear
amplification-mediated PCR, and bioinformatic analysis of integra-
tion sites was performed as described previously.10
To analyze the sequencing data, sample-specific barcoded sequencing
reads were demultiplexed using CASAVA, an Illumina software
package. The quality of sequencing runs of resulting fastq files was
evaluated using FastQC (http://www.bioinformatics.babraham.ac.
uk/projects/fastqc). Reads starting with the barcode 50-GTATGT
AAACTTCCGACTTCAACTG-30 that follows the TA dinucleotide,
which is characteristic of SB integration, were aligned against the lat-
est version of mouse reference genome (GRCm38/mm10 [December
2011]) using Bowtie2.49 Only reads that mapped exactly to a unique
position in the reference genome were kept for further analysis. To
analyze the distribution integrations, annotations of exons, and cod-
ing DNA sequence (CDS) of the corresponding reference, genome
were downloaded and the percentage of integration sites overlapping
with the given genomic coordinates was analyzed using BEDTools.50
We have indexed and created 142 normal, shuffled, and randomized
windows of mouse genome and counted the number of integrations
for each window and plotted the density.Animals
All experiments involving animals were conducted in accordance with
the institutional guidelines set forth by the University of Washington.
The University of Washington is an Association for the Assessment
and Accreditation of Laboratory Animal Care International
(AALAC)-accredited research institution, and all live animal work
conducted at this university is in accordance with the Office of
Laboratory Animal Welfare (OLAW) Public Health Assurance
(PHS) policy, USDA Animal Welfare Act and Regulations, the Guide
for the Care and Use of Laboratory Animals, and the University of
Washington’s Institutional Animal Care and Use Committee
(IACUC) policies. The studies were approved by the University of
Washington IACUC (Protocol No. 3108-01).
The immunodeficient NOD/Shi-scid/IL-2Rgnull (NSG) mice were
obtained from Jackson Laboratory (Bar Harbor, ME). For HSC trans-
plantation, NSG recipient mice received 300 Rad whole-body irradi-
ation. 2.5  105 whole bone marrow cells of non-irradiated NOG
mice were mixed with 6  105 transduced human CD34+ cells and
injected intravenously into recipient mice at 4 hr post irradiation.
For transplantation into C57BL/6 mice, animals were irradiated
with 1,000 Rad. 4 hr after irradiation, transduced HSCs were injected
intravenously through the tail vein at 1  106 cells per mouse.Statistical Analyses
For comparisons of multiple groups, one-way and two-way ANOVA
with Bonferroni post-testing for multiple comparisons was employed.18
www.moleculartherapy.orgStatistical analysis was performed using GraphPad Prism version 6.01
(GraphPad Software, La Jolla, CA).
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